Tosti A, Piraccini B M, Stinchi C, Venturo N, Bardazzi F, Colombo M D
Department of Dermatology, University of Bologna, Italy.
J Am Acad Dermatol. 1996 Apr;34(4):595-600. doi: 10.1016/s0190-9622(96)80057-0.
terbinafine persists in the nail at effective concentrations for several weeks after discontinuation of treatment.
Our purpose was to verify whether intermittent terbinafine therapy is effective in dermatophytic onychomycosis and to compare the results of intermittent terbinafine with those of intermittent itraconazole and continuous terbinafine treatment.
An open, randomized study of 63 patients was performed with three treatment regimens: terbinafine, 250 mg daily (21 patients); terbinafine, 500 mg daily for 1 week every month (21 patients); or itraconazole, 400 mg daily for 1 week every month (21 patients). Treatment was continued for 4 months in toenail infections (60 patients) and 2 months in fingernail infections (3 patients).
At the end of the follow-up period (6 months after discontinuation of treatment) 16 of the 17 patients (94.1%) with toenail onychomycosis were mycologically cured in the terbinafine 250 mg group, 16 of 20 (80%) in the terbinafine 500 mg group, and 15 of 20 (75%) in the itraconazole group.
The percentage of patients who were mycologically cured was higher in the continuous terbinafine group than in the intermittent terbinafine and itraconazole groups, but statistical analysis did not reveal any significant difference between these cure rates.
特比萘芬在停药后数周内仍以有效浓度存在于指甲中。
我们的目的是验证间歇性特比萘芬疗法对皮肤癣菌性甲真菌病是否有效,并比较间歇性特比萘芬与间歇性伊曲康唑及连续性特比萘芬治疗的结果。
对63例患者进行了一项开放性随机研究,采用三种治疗方案:特比萘芬,每日250毫克(21例患者);特比萘芬,每月每日500毫克,共1周(21例患者);或伊曲康唑,每月每日400毫克,共1周(21例患者)。趾甲感染(60例患者)治疗持续4个月,指甲感染(3例患者)治疗持续2个月。
在随访期结束时(停药后6个月),特比萘芬250毫克组17例趾甲甲真菌病患者中有16例(94.1%)真菌学治愈,特比萘芬500毫克组20例中有16例(80%),伊曲康唑组20例中有15例(75%)。
连续性特比萘芬组真菌学治愈的患者百分比高于间歇性特比萘芬组和伊曲康唑组,但统计分析未显示这些治愈率之间有任何显著差异。